Comparative Pharmacology
Head-to-head clinical analysis: METRO I V versus METROCREAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V versus METROCREAM.
METRO I.V. vs METROCREAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
Topical, apply a thin film to affected area once or twice daily.
None Documented
None Documented
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)